A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
Identifieur interne : 000695 ( Pmc/Curation ); précédent : 000694; suivant : 000696A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
Auteurs : Feng Tian ; Jing-Yang Li ; Zhen-Hua Wen ; Xiao-Wen Luo ; Li Deng ; Liang Zhang ; Jing-Yun HeSource :
- Medicine [ 0025-7974 ] ; 2019.
Abstract
Supplemental Digital Content is available in the text
Url:
DOI: 10.1097/MD.0000000000017750
PubMed: 31770193
PubMed Central: 6890288
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000695
Links to Exploration step
PMC:6890288Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients</title>
<author><name sortKey="Tian, Feng" sort="Tian, Feng" uniqKey="Tian F" first="Feng" last="Tian">Feng Tian</name>
</author>
<author><name sortKey="Li, Jing Yang" sort="Li, Jing Yang" uniqKey="Li J" first="Jing-Yang" last="Li">Jing-Yang Li</name>
</author>
<author><name sortKey="Wen, Zhen Hua" sort="Wen, Zhen Hua" uniqKey="Wen Z" first="Zhen-Hua" last="Wen">Zhen-Hua Wen</name>
</author>
<author><name sortKey="Luo, Xiao Wen" sort="Luo, Xiao Wen" uniqKey="Luo X" first="Xiao-Wen" last="Luo">Xiao-Wen Luo</name>
</author>
<author><name sortKey="Deng, Li" sort="Deng, Li" uniqKey="Deng L" first="Li" last="Deng">Li Deng</name>
</author>
<author><name sortKey="Zhang, Liang" sort="Zhang, Liang" uniqKey="Zhang L" first="Liang" last="Zhang">Liang Zhang</name>
</author>
<author><name sortKey="He, Jing Yun" sort="He, Jing Yun" uniqKey="He J" first="Jing-Yun" last="He">Jing-Yun He</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31770193</idno>
<idno type="pmc">6890288</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890288</idno>
<idno type="RBID">PMC:6890288</idno>
<idno type="doi">10.1097/MD.0000000000017750</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000695</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000695</idno>
<idno type="wicri:Area/Pmc/Curation">000695</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000695</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients</title>
<author><name sortKey="Tian, Feng" sort="Tian, Feng" uniqKey="Tian F" first="Feng" last="Tian">Feng Tian</name>
</author>
<author><name sortKey="Li, Jing Yang" sort="Li, Jing Yang" uniqKey="Li J" first="Jing-Yang" last="Li">Jing-Yang Li</name>
</author>
<author><name sortKey="Wen, Zhen Hua" sort="Wen, Zhen Hua" uniqKey="Wen Z" first="Zhen-Hua" last="Wen">Zhen-Hua Wen</name>
</author>
<author><name sortKey="Luo, Xiao Wen" sort="Luo, Xiao Wen" uniqKey="Luo X" first="Xiao-Wen" last="Luo">Xiao-Wen Luo</name>
</author>
<author><name sortKey="Deng, Li" sort="Deng, Li" uniqKey="Deng L" first="Li" last="Deng">Li Deng</name>
</author>
<author><name sortKey="Zhang, Liang" sort="Zhang, Liang" uniqKey="Zhang L" first="Liang" last="Zhang">Liang Zhang</name>
</author>
<author><name sortKey="He, Jing Yun" sort="He, Jing Yun" uniqKey="He J" first="Jing-Yun" last="He">Jing-Yun He</name>
</author>
</analytic>
<series><title level="j">Medicine</title>
<idno type="ISSN">0025-7974</idno>
<idno type="eISSN">1536-5964</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Supplemental Digital Content is available in the text</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Chinese Rheumatology, A" uniqKey="Chinese Rheumatology A">A Chinese Rheumatology</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Mcinnes, Ib" uniqKey="Mcinnes I">IB McInnes</name>
</author>
<author><name sortKey="Schett, G" uniqKey="Schett G">G Schett</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name>
</author>
<author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name>
</author>
<author><name sortKey="Mcinnes, Ib" uniqKey="Mcinnes I">IB McInnes</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Burmester, Gr" uniqKey="Burmester G">GR Burmester</name>
</author>
<author><name sortKey="Pope, Je" uniqKey="Pope J">JE Pope</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Malmstrom, V" uniqKey="Malmstrom V">V Malmstrom</name>
</author>
<author><name sortKey="Catrina, Ai" uniqKey="Catrina A">AI Catrina</name>
</author>
<author><name sortKey="Klareskog, L" uniqKey="Klareskog L">L Klareskog</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lefevre, S" uniqKey="Lefevre S">S Lefevre</name>
</author>
<author><name sortKey="Knedla, A" uniqKey="Knedla A">A Knedla</name>
</author>
<author><name sortKey="Tennie, C" uniqKey="Tennie C">C Tennie</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Isaacs, Jd" uniqKey="Isaacs J">JD Isaacs</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Brennan, A" uniqKey="Brennan A">A Brennan</name>
</author>
<author><name sortKey="Bansback, N" uniqKey="Bansback N">N Bansback</name>
</author>
<author><name sortKey="Nixon, R" uniqKey="Nixon R">R Nixon</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Brennan, A" uniqKey="Brennan A">A Brennan</name>
</author>
<author><name sortKey="Bansback, N" uniqKey="Bansback N">N Bansback</name>
</author>
<author><name sortKey="Reynolds, A" uniqKey="Reynolds A">A Reynolds</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Soini, Ej" uniqKey="Soini E">EJ Soini</name>
</author>
<author><name sortKey="Hallinen, Ta" uniqKey="Hallinen T">TA Hallinen</name>
</author>
<author><name sortKey="Puolakka, K" uniqKey="Puolakka K">K Puolakka</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Bansback, N" uniqKey="Bansback N">N Bansback</name>
</author>
<author><name sortKey="Phibbs, Cs" uniqKey="Phibbs C">CS Phibbs</name>
</author>
<author><name sortKey="Sun, H" uniqKey="Sun H">H Sun</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Jalal, H" uniqKey="Jalal H">H Jalal</name>
</author>
<author><name sortKey="O Ell, Jr" uniqKey="O Ell J">JR O’Dell</name>
</author>
<author><name sortKey="Bridges, Sl" uniqKey="Bridges S">SL Bridges</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Chen, Xx" uniqKey="Chen X">XX Chen</name>
</author>
<author><name sortKey="Dai, Q" uniqKey="Dai Q">Q Dai</name>
</author>
<author><name sortKey="Huang, Ab" uniqKey="Huang A">AB Huang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Chen, Xx" uniqKey="Chen X">XX Chen</name>
</author>
<author><name sortKey="Li, Zg" uniqKey="Li Z">ZG Li</name>
</author>
<author><name sortKey="Wu, Hx" uniqKey="Wu H">HX Wu</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Carreno, A" uniqKey="Carreno A">A Carreno</name>
</author>
<author><name sortKey="Fernandez, I" uniqKey="Fernandez I">I Fernandez</name>
</author>
<author><name sortKey="Badia, X" uniqKey="Badia X">X Badia</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Wouters, Oj" uniqKey="Wouters O">OJ Wouters</name>
</author>
<author><name sortKey="Naci, H" uniqKey="Naci H">H Naci</name>
</author>
<author><name sortKey="Samani, Nj" uniqKey="Samani N">NJ Samani</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Davies, A" uniqKey="Davies A">A Davies</name>
</author>
<author><name sortKey="Cifaldi, Ma" uniqKey="Cifaldi M">MA Cifaldi</name>
</author>
<author><name sortKey="Segurado, Og" uniqKey="Segurado O">OG Segurado</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
<journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
<journal-id journal-id-type="publisher-id">MEDI</journal-id>
<journal-title-group><journal-title>Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">0025-7974</issn>
<issn pub-type="epub">1536-5964</issn>
<publisher><publisher-name>Wolters Kluwer Health</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">31770193</article-id>
<article-id pub-id-type="pmc">6890288</article-id>
<article-id pub-id-type="publisher-id">MD-D-19-02687</article-id>
<article-id pub-id-type="doi">10.1097/MD.0000000000017750</article-id>
<article-id pub-id-type="art-access-id">17750</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>6900</subject>
</subj-group>
<subj-group><subject>Research Article</subject>
<subject>Observational Study</subject>
</subj-group>
</article-categories>
<title-group><article-title>A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Tian</surname>
<given-names>Feng</given-names>
</name>
<degrees>MM</degrees>
</contrib>
<contrib contrib-type="author"><name><surname>Li</surname>
<given-names>Jing-Yang</given-names>
</name>
<degrees>MB</degrees>
<xref rid="cor1" ref-type="corresp"><sup>∗</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wen</surname>
<given-names>Zhen-Hua</given-names>
</name>
<degrees>MM</degrees>
</contrib>
<contrib contrib-type="author"><name><surname>Luo</surname>
<given-names>Xiao-Wen</given-names>
</name>
<degrees>MB</degrees>
</contrib>
<contrib contrib-type="author"><name><surname>Deng</surname>
<given-names>Li</given-names>
</name>
<degrees>MM</degrees>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname>
<given-names>Liang</given-names>
</name>
<degrees>MB</degrees>
</contrib>
<contrib contrib-type="author"><name><surname>He</surname>
<given-names>Jing-Yun</given-names>
</name>
<degrees>MB</degrees>
</contrib>
</contrib-group>
<contrib-group><contrib contrib-type="editor"><name><surname>Tsuji.</surname>
<given-names>Fumio</given-names>
</name>
</contrib>
</contrib-group>
<aff>Department of Rheumatology and Immunology, ZhuZhou Central Hospital, The Affiliated ZhuZhou Hospital XiangYa Medical College CSU, Zhuzhou, China.</aff>
<author-notes id="cor1"><corresp><label>∗</label>
Correspondence: Jing-Yang Li, Department of Rheumatology and Immunology, ZhuZhou Central Hospital, The Affiliated ZhuZhou Hospital XiangYa Medical College CSU, 116 South Changjiang Road, Tianyuan District, Zhuzhou 412007, China (e-mail: <email>yongchuo3173423355@163.com</email>
).</corresp>
</author-notes>
<pub-date pub-type="collection"><month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub"><day>27</day>
<month>11</month>
<year>2019</year>
</pub-date>
<volume>98</volume>
<issue>48</issue>
<elocation-id>e17750</elocation-id>
<history><date date-type="received"><day>13</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="rev-recd"><day>27</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted"><day>02</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>
</license-p>
</license>
</permissions>
<self-uri xlink:type="simple" xlink:href="medi-98-e17750.pdf"></self-uri>
<abstract abstract-type="toc"><p>Supplemental Digital Content is available in the text</p>
</abstract>
<abstract><title>Abstract</title>
<p>The aim of this study was to evaluate the cost-effectiveness of Anbainuo (ABN) plus methotrexate (MTX) (ABN + MTX) versus conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients.</p>
<p>Forty-eight moderate to severe RA patients underwent ABN + MTX or cDMARDs treatment were consecutively enrolled and assigned to ABN + MTX group (n = 26) and control group (n = 22). Patients were followed up and their disease activity and quality of life (QoL) were evaluated at 3rd month, 6th month and 12th month after initiation of treatment. Treatment costs of 2 groups were calculated, then pharmacoeconomic analysis was performed.</p>
<p>ABN + MTX increased drug cost and total cost while decreased indirect cost compared with cDMARDs after 12-month treatment. ABN + MTX group gained additional 0.22 quality-adjusted life years (QALY) and yielded an incremental cost-effectiveness ratio (ICER) of ¥104,293.6 per QALY after treatment. Sensitivity analysis reveals that rising ABN price by 20% produced an ICER of ¥130,403.6 per QALY, which was still lower than 3 times of the mean gross domestic product (GDP) per capita during the same period in China (¥165,960). Besides, ABN + MTX was more cost-effective in severe RA patients compared to moderate RA patients.</p>
<p>ABN + MTX is cost-effective in treating moderate to severe RA patients compared with cDMARDs, although the total cost of ABN + MTX is relatively higher.</p>
</abstract>
<kwd-group><title>Keywords</title>
<kwd>anbainuo</kwd>
<kwd>conventional disease modifying antirheumatic drugs</kwd>
<kwd>cost-effectiveness</kwd>
<kwd>price</kwd>
<kwd>rheumatoid arthritis</kwd>
</kwd-group>
<custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:6890288 |texte= A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:31770193" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |